Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 45 clinical trials
Central Nervous System Disorders Following Hematopoietic Stem Cell Transplantation

All patients undergoing allogeneic or autologous HSCT at the participating centres will be observed. Once a diagnosis of CNS disorder is made, additional data will be reported for these patients. We will identify clinical and diagnostic characteristics such as cerebrospinal fluid (CSF) and neuroimaging patterns, risk factors, response to treatment …

  • 0 views
  • 05 May, 2021
  • 5 locations
Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment

> One of the more recent approved medical treatments for MS patients is Alemtuzumab (product name Lemtrada), a humanized monoclonal antibody targeting CD52 cells, that depletes and repopulates B

  • 0 views
  • 22 Jan, 2021
Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers for Risk Stratification and Treatment Response

Alemtuzumab is a highly effective therapy in relapse remitting multiple sclerosis (RRMS). The aim of this study is to elucidate the mechanism of action of the neuroprotective potential of

  • 0 views
  • 23 Jan, 2021
Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT BMT or PBSCT With RIC

This is a data collection study that will examine the general diagnostic and treatment data associated with the reduced-intensity chemotherapy-based regimen paired with simple alemtuzumab dosing

  • 0 views
  • 26 Jan, 2021
  • 1 location
Observatory of Prolymphocytic Leukemia T

response to conventional chemotherapy. Treatment with the anti-CD52 monoclonal antibody: alemtuzumab has considerably improved the results, but the responses to treatment are transient; therefore

AKT
monoclonal antibodies
  • 0 views
  • 24 Jan, 2021
  • 1 location